{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '5.3.', 'Participant and Study Completion', 'A participant will be considered to have completed the study if he or she has received at', 'least one dose of the study treatment and, has died or is still in follow-up when the study', 'is closed, and has not withdrawn consent from study participation.', 'The study will end when 60% of the participants have died, OR withdrawn consent, OR', 'are lost to follow-up, AND all participants with corneal events have been followed for up', 'to 12 months after last dose of treatment. At this time, end of study analyses will be', 'performed. If a participant remains on treatment at the time end of study is achieved, they', 'may be offered an option to extend treatment on another protocol. A participant will be', 'considered to have withdrawn from the study if:', '(a) the participant has not died and is lost to follow-up,', '(b) the participant has withdrawn consent,', \"(c) the participant is no longer being followed at the investigator's discretion, or\", '(d) the study is terminated prematurely.', 'Documentation of the cause of death in the electronic Case Report Form (eCRF) is', 'required for all participants who die in the study regardless of the cause of death.', '5.4.', 'Scientific Rationale for Study Design', 'Patients with RRMM who have relapsed after prior treatment with an anti-CD38 antibody', 'and are refractory to a PI and an IMiD represent a population of unmet medical need, for', 'whom there is no approved treatment option. Given the clinical activity demonstrated in', 'the BMA117159 study, treatment with GSK2857916 may offer a benefit to this patient', 'population. It is also expected that due to its unique mechanism of action, GSK2857916', 'may be able to overcome the resistance to previously used drugs in the MM population.', 'GSK2857916 is the first-in-class ADC targeting BCMA. Preliminary clinical data for', 'GSK2857916 monotherapy from Study BMA117159 among 35 participants indicate an', 'ORR of 60% [95% CI: 42.1%, 76.1%], with 51% of participants (n=18) having deep', 'responses of VGPR or better. The median DoR has not been achieved, the 25th percentile', 'for DoR is 6.7 months; the median PFS in this population was 7.9 months [95% CI: 3.1,', 'NA]. Of note, the ORR for participants previously treated with daratumumab (n=14) was', '43% (95% CI: 17.7, -71.1). Fifty nine percent of the treated population had 5 of more', 'prior treatments.', 'The response rate observed in this population is higher than response rates observed in', 'similarly defined patient populations treated with other recently approved drugs (ORR', 'ranging from 23.7% to 33.1% for Carfilzomib, pomalidomide and daratumumab)', '[Siegel, 2012; Usmani, 2016; Kumar, 2008]. Given the evidence of clinical activity and', 'manageable safety/tolerability profile demonstrated to date, the current evidence supports', 'further development.', '47']['2017N330177_04', 'CONFIDENTIAL', '205678', 'The two-arm design with two dose levels and a futility analysis is justified for this', 'population because there is no approved comparator for the proposed treatment setting.', 'In Study BMA117159, the maximum clinical benefit (ORR) was observed at the 3.4', 'mg/kg dose level, but a significant number of participants required dose delays and dose', 'reductions. At lower dose levels, the results were variable, with wide confidence', 'intervals. In order to generate additional safety and efficacy data at a lower dose while', 'providing participants a chance of deriving clinical benefit, the dose of 2.5 mg/kg has', 'been selected for additional testing (see Section 5.5 for dose justification).', 'This design is appropriate for the selected patient population, since there is no approved', 'standard of care in patients failing daratumumab. As shown in earlier studies on a similar', 'population, the response rate is low and the mPFS is short in those patients. For example,', 'in the pomalidomide + dexamethasone (PomDex) VS pomalidomide (Pom) study that', 'enrolled patients with median of 5 prior lines, among whom 61% have been refractory to', 'the mainstay of treatment, lenalidomide and bortezomib had an ORR of 18%, and mPFS', 'of 2.7 months on Pom monotherapy arm [Richardson, 2013]. A similar Phase3 study of', 'Pom with low dose dexamethasone (Pom/loDex) VS high dose dexamethasone (HiDex)', 'has demonstrated an ORR of 3.9%, mPFS of 1.8 months, and mOS of 8 months in the', 'HiDex arm where patients had a median of 5 prior lines, and 74% of them were double', 'refractory to lenalidomide and bortezomib [Weisel, 2013].', 'Further, a randomized, phase III study which compared carfilzomib monotherapy against', 'low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory', 'multiple myeloma has demonstrated an ORR of 11%, and OS of 10 months in', 'populations previously treated with 5 lines of therapy and 63% of patients were double', 'refractory to bortezomib and IMiD [H\u00e1jek, 2017]. In summary, these examples provide', 'indirect evidence that the prognosis of patients eligible for this protocol is poor, and that', 'selected threshold for claiming success (33%) is appropriate since it doubles the expected', 'ORR for those patients when treated with available agents.', '5.5.', 'Dose Justification', 'GSK2857916 is currently being studied in the Phase I FTIH study, BMA117159. As of', 'the clinical cut-off date of 26 June 2017, a total of 73 participants with RRMM have', 'received at least 1 dose of GSK2857916.', 'Participants in Study BMA117159 were enrolled into the dose-escalation phase of the', 'study (Part 1) at the following dose levels: 0.03 mg/kg (n=1), 0.06 mg/kg (n=1), 0.12', 'mg/kg (n=4), 0.24 mg/kg (n=4), 0.48 mg/kg (n=4), 0.96 mg/kg (n=3), 1.92 mg/kg (n=4),', '2.50 mg/kg (n=8), 3.40 mg/kg (n=3), and 4.60 mg/kg (n=6). Based on the data from Part', '1 of the study, 35 participants were treated in the Dose Expansion portion (Part 2) at 3.4', 'mg/kg Q3W.', 'Clinical activity in Study BMA117159', 'Clinical activity at the tested dose levels in Part 1 is summarized in Table 7. There were', 'no dose-limiting toxicities (DLTs) observed during dose escalation; however, there was', 'limited tolerability of the 4.6 mg/kg dose (prolonged fever, headache, severe fatigue).', '48']\n\n###\n\n", "completion": "END"}